Wavelength-Pharmaceuticals-Insert
X

Find Novel Neurology Drugs in Preclinical Development

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tau and Alpha-synuclein vectorized antibody

            Therapeutic Area: Neurology Product Name: Alpha-synuclein vectorized antibody

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: AbbVie Inc

            Deal Size: $250.9 million Upfront Cash: Undisclosed

            Deal Type: Termination August 03, 2020

            Details:

            Voyager retains full rights to the vectorization technology and certain novel vectorized antibodies developed as part of the collaborations.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Anti-TDP-43 antibody

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 03, 2020

            Details:

            Advancing the anti-TDP-43 antibody towards clinical development is the latest in a series of important milestones already achieved this year in the Company’s cutting-edge therapeutic and diagnostic programs targeting TDP-43 – which are amongst the most comprehensive in the field.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AAV based gene regulation therapy

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation

            Deal Size: $795.0 million Upfront Cash: $75.0 million

            Deal Type: Collaboration July 30, 2020

            Details:

            Sangamo’s propriety genome regulation technology, zinc finger protein transcription factors (ZFP-TFs), aim to develop gene regulation therapies to address three neurodevelopmental targets, including autism spectrum disorder (ASD) and other neurodevelopmental disorders.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): EQ-6

            Therapeutic Area: Neurology Product Name: EQ-6

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 27, 2020

            Details:

            AxoProtego has licensed the rights for the worldwide development and commercialization of Ethoxyquin and its derivatives (including EQ-6, its lead compound) from The Johns Hopkins University.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Oxytocin

            Therapeutic Area: Neurology Product Name: TNX-1900

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 27, 2020

            Details:

            Preclinical results of TNX-1900 (oxytocin solution for intranasal delivery) will be presented in a poster at the American Academy of Neurology’s first-ever Sports Concussion Conference.

            National Institute of Neurological Disorders

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Enol-oxaloacetate

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: MetVital

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration July 24, 2020

            Details:

            AEO, a patented molecule, is MetVital's lead clinical development drug candidate and has been approved for commercial Phase 2 testing of Glioblastoma multiforme, a malicious type of brain cancer, and the seizures caused by the cancer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ETX101

            Therapeutic Area: Neurology Product Name: ETX101

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: GV

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Series D Financing July 22, 2020

            Details:

            ETX101, Encoded's lead asset, was granted Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation by FDA for the treatment of SCN1A+ Dravet Syndrome.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Arimoclomol

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Michael J. Fox Foundation

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration July 17, 2020

            Details:

            Orphazyme’s drug candidate arimoclomol has potential across a range of neurodegenerative diseases, including GCase-deficient Parkinson’s disease (PD).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): KB-3061

            Therapeutic Area: Neurology Product Name: KB-3061

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 15, 2020

            Details:

            Knopp is advancing the development of KB-3061 as a potential precision medicine for KCNQ2-EE, a rare genetic disease associated with seizures beginning in the first days of life and profound neurodevelopmental delay.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TQS-168

            Therapeutic Area: Neurology Product Name: TQS-168

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Remiges Ventures

            Deal Size: $30.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing July 09, 2020

            Details:

            The financing will support company's novel platform based on groundbreaking research from the laboratory of Professor Edgar Engleman, MD, at Stanford University indicating that myeloid immune cell dysfunction underlies a variety of nervous system disorders.

            PharmaCompass